JAIDS Journal of Acquired Immune Deficiency Syndromes:
Persistence of Nevirapine Exposure During the Postpartum Period After Intrapartum Single-Dose Nevirapine in Addition to Zidovudine Prophylaxis for the Prevention of Mother-to-Child Transmission of HIV-1
Cressey, Tim R PhD*†; Jourdain, Gonzague MD*†; Lallemant, Marc J MD†‡; Kunkeaw, Suparat BSc†; Jackson, J Brooks MD§; Musoke, Philippa MBChB∥; Capparelli, Edmund PharmD¶; Mirochnick, Mark MD#
From the *Harvard School of Public Health, Boston, MA; †Institut de Recherche pour le Développement, 054 Perinatal HIV Prevention Trial, Chiang Mai, Thailand; ‡Institut de Recherche pour le Développement, UR 054, Chiang Mai, Thailand; §Johns Hopkins School of Medicine, Baltimore, MD; ∥Makerere University, Kampala, Uganda; ¶University of California Pediatric Pharmacology Research Unit, San Diego, CA; and #Boston University School of Medicine, Boston, MA.
Received for publication July 9, 2004; accepted October 21, 2004.
Supported by National Institutes of Health (NIH) grant R01 39615, French National Agency for AIDS Research grant 12-08, and the Institut de Recherche pour le Développement. The HIVNET 006 study was supported by the HIV Network for Prevention Trials (HIVNET) and the US National Institute of Allergy and Infectious Diseases (NIAID), NIH, through contracts N01-A1-35173 and N01-A1-45200 and subcontract number N01-A1-35173-147. The PACTG 250 study was supported by the Pediatric AIDS Clinical Trials Group of the NIAID and by the Pediatric/Perinatal HIV Clinical Trials Network of the National Institute of Child Health and Human Development.
Reprints: Tim R. Cressy, PO Box 207, Prasing Post, Muang, Chiang Mai, 50205, Thailand (e-mail: email@example.com).
Objective: To determine nevirapine (NVP) plasma levels during the postpartum period after a single intrapartum NVP dose for the prevention of mother-to-child transmission.
Methods: Plasma samples at delivery and during days 8 to 45 postpartum were obtained from HIV-infected Thai women who received an intrapartum NVP dose in the Perinatal HIV Prevention Clinical Trial-2 (PHPT-2) for the prevention of perinatal HIV transmission. These data were combined with NVP concentration data from 2 phase 1 studies of NVP for a population analysis.
Results: The median NVP level fell to 68 ng/mL (range: <50-228, n = 43) 8 to 14 days after dosing and to 51 ng/mL (range: <50-166, n = 25) between 15 and 21 days. During the second and third weeks postpartum, NVP levels were below the limit of quantitation in 23% and 44% of samples, respectively. Between 21 and 45 days, no sample had a quantifiable NVP concentration. A simulation derived from the population analysis predicts that NVP concentration falls to less than 10 ng/mL in 5% of women by 11 days, in 50% of women by 17.5 days, and in 95% of women by 28 days.
Conclusions: Significant NVP concentrations remained for up to 20 days in these Thai women. To ensure that coverage is maintained until NVP concentrations fall to nonsuppressive levels, 1 month of additional antiretroviral treatment after delivery should be considered to prevent the emergence of resistant viruses.
Although suboptimal when compared with the treatment of maternal HIV-1 infection with highly active antiretroviral therapy (HAART),1 several lower intensity antiretroviral regimens using zidovudine (ZDV) alone or in combination with lamivudine (3TC) or nevirapine (NVP) alone have been shown to significantly reduce mother-to-child HIV transmission.2-4 Recently, in Thailand, the Perinatal HIV Prevention Clinical Trial (PHPT-2) study demonstrated that combining a single NVP dose administered to women at the onset of labor and to their infants at 48 to 72 hours after birth with ZDV prophylaxis starting at 28 weeks of gestation reduced transmission similar to rates observed with HAART during pregnancy.5
Enthusiasm for the use of NVP for prevention of mother-to-child HIV transmission has been tempered by the observation that exposure of pregnant women to a single intrapartum NVP dose is frequently associated with the selection of high-level nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant viruses during the postpartum period. NNRTI resistance results from a single mutation, such as the K103N mutation, in the reverse transcriptase gene. Early in the development of NVP, it was observed that NVP monotherapy can select such resistant viruses after as little as 1 week of exposure.6 In the HIV Network for Prevention Trial (HIVNET) 012, where a single intrapartum NVP dose was used without ZDV, NNRTI-resistant virus was detected in 19% of 111 women tested 6 to 8 weeks after delivery.7 In the Pediatric AIDS Clinical Trials Group (PACTG) 316 study, where women received various combination antiretroviral regimens during pregnancy plus single intrapartum NVP doses, NNRTI-resistant virus was detected in 15% of 95 women at 6 weeks postpartum.8 In all these studies, the K103N mutation was the most common mutation detected.
NVP is highly lipophilic and readily absorbed (>90%) after oral administration in adults, remains essentially nonionized at physiologic pH, readily crosses the placenta, and has a reported half-life of 45 hours (single dose) and 25 to 30 hours (multiple doses).9,10 Phase 1 studies of the safety and pharmacokinetics of NVP in Ugandan and American women demonstrated that 200-mg doses administered to HIV-infected women during labor were rapidly absorbed and achieved NVP concentrations more than 10 times the concentration required to inhibit by 50% (IC50) value in the newborn at delivery.11,12 When the infant received an additional 2-mg/kg dose at 48 to 72 hours of life, infant NVP concentration was maintained at greater than the target of 100 ng/mL through the age of 7 days.11,12 The mothers in both studies demonstrated prolonged elimination of NVP, with a reported median elimination half-life (T1/2) of 61.3 hours (range: 27-90 hours) in the Ugandan women. Sampling in both studies stopped 7 days after dosing, and NVP concentrations in the final samples ranged from 40 to 596 ng/mL.
To date, no data on NVP plasma concentrations beyond 1 week postpartum are available in HIV-infected pregnant women receiving single-dose NVP during labor. The objective of this study was to determine the length of time during which NVP was present in the plasma of women after a single NVP dose at the onset of labor for the prevention of mother-to-child HIV transmission to help define the period when there is a risk of developing NVP resistance postpartum and when specific interventions such as a short course of additional antiretroviral treatment could prevent this risk.
The study database consisted of plasma NVP concentrations collected from Thai women. All study women were infected with HIV and received a single dose of NVP during labor. Eighty-one of the Thai women were participants in the PHPT-2, a multicenter, randomized, 3-arm, double-blind, controlled study assessing the efficacy in preventing mother-to-child HIV transmission of single-dose NVP given at the onset of labor and to the infant 48 to 72 hours after birth in addition to ZDV starting at 28 weeks of gestation or as soon as possible thereafter. Plasma samples were also obtained from 26 Thai women who were participants in a pilot pharmacokinetics (PK) substudy performed before initiation of PHPT-2 and from 3 Thai women who received open-label single-dose nevirapine because they had not completed the required 2 weeks of ZDV prophylaxis before enrollment in the PHPT-2.
In the PHPT-2, blood draws were scheduled for mothers immediately after delivery as well as 10 days, 6 weeks, and 4 months postpartum for pharmacokinetic and virologic studies. Patient samples were selected based on the timing of their postpartum sample and time of NVP intake. Women who received a placebo or more than 1 dose of NVP (ie, for false labor or a prolonged labor) were excluded. No concomitant treatments with drugs that affect NVP pharmacokinetics were used in these women. Plasma samples for NVP assay were obtained from at least 2 time points: at delivery and between 8 and 45 days after dosing. In women participating in the pilot NVP substudy before PHPT-2, samples were also available 1 day after delivery. A total of 241 samples were assayed from 110 Thai women. All patients provided written informed consent, and the PHPT-2 study was approved by the Ethics Committee of the Harvard School of Public Health; Ministry of Public Health, Thailand; and Faculty of Associated Medical Sciences (AMS), Chiang Mai University, Thailand. The data from these Thai women were then nested in a population analysis as described below with the data from previously published phase 1 pharmacokinetic protocols of single intrapartum dosing in Ugandan and American women.11,12
Sample Preparation and Nevirapine Assay
Blood samples were centrifuged, and the plasma was aliquoted and frozen within 1 hour of collection at −20°C. NVP plasma drug concentrations were measured at the Faculty of Associated Medical Sciences (AMS), Chiang Mai University, by a validated high-performance liquid chromatography (HPLC) assay described previously.13 The lower limit of assay quantitation (LLQ) was 50 ng/mL. This method was validated in the laboratory in Chiang Mai using the AIDS Clinical Trials Group (ACTG) method validation guidelines with inter- and intra-assay variability of a coefficient of variation (CV) <15% at the LLQ and CV <20% at 3 levels of the calibration curve. The laboratory participates in the international external quality control (QC) programs of the ACTG,14 Pharmacology Quality Control (Precision Testing) program, and ASQUALAB, France.15 Patient plasma samples and all calibration and control samples were heat-inactivated in a water bath at 56°C for 30 minutes before assay. Sample preparation and NVP assay methodology for the samples from the Ugandan and American women have been previously described.11,12
Population Pharmacokinetic Analysis
NVP plasma concentration data from the Thai women were combined with those from the previously published phase 1 studies. Because no samples collected beyond 21 days after dosing had quantifiable NVP concentrations, only samples collected before 21 days after dosing were included in the population database. Population pharmacokinetic analysis of the combined database was performed using the population mixed-effect modeling program NONMEM (version 5.1) with an MS Powerstation Fortran Compiler (Microsoft Corp, Redmond, WA).16 Model development was performed in 3 steps: (1) development of an initial pharmacokinetic model, (2) evaluation of patient characteristics as potential covariates of pharmacokinetic parameters, and (3) optimization of the final model.17 The effects of individual covariates on model fit were evaluated independently. All significant covariates were then added to the model and removed 1 at a time in order of decreasing improvement in the objective function. Only covariates showing a significant contribution were conserved in this intermediate model. After all significant patient characteristics had been evaluated in this way, each included covariate was re-evaluated, and only those parameters that continued to improve the fit of the model significantly were retained. After the final structural model was accepted, different error models were evaluated. The final structural and error model was then re-evaluated with first-order conditional estimation. The resulting pharmacokinetic parameters were used in a Monte Carlo simulation of 1000 subjects to generate NVP concentration-time plots from intrapartum dosing through 30 days after dosing.
Table 1 shows the baseline characteristics of the Thai women, which were similar to those observed in the entire PHPT-2 population. No concomitant treatments with drugs that affect NVP pharmacokinetics were used by these patients. At delivery, median weight was 63 kg (range: 40-106 kg) for the 110 Thai women compared with 61.5 kg (range: 48-72 kg) for the 20 Ugandan women and 69 kg (range: 48-138 kg) for the 10 American women included in the population analysis.
Nevirapine Pharmacokinetics at Delivery
NVP plasma levels were measured immediately after delivery in 110 Thai women. All women had detectable NVP levels at delivery, and Figure 1 shows the individual NVP plasma concentrations measured. The median time between NVP intake and blood draw at delivery was 7.9 hours (range: 0.2-47 hours), and the median NVP plasma level at delivery was 1695 ng/mL (range: 161-3737 ng/mL).
Postpartum Nevirapine Pharmacokinetics
For each of the 110 Thai patients, single NVP plasma levels were also measured during the postpartum period, and the time between NVP intake and their first postpartum visit and blood draw varied from 8 to 45 days. Figure 1 shows the individual NVP plasma concentrations measured for each patient during this postpartum period. NVP was detectable in plasma up to 21 days postpartum.
Patient NVP postpartum plasma level results were separated based on the time between NVP intake and blood draw postpartum. Forty-three samples were available between 1 and 2 weeks postpartum (range: 8-14 days), and the median NVP level was 68 ng/mL (range: ≤50-228 ng/mL). Between 2 and 3 weeks postpartum (range: 15-21 days), 25 samples were available, and the median NVP concentration was 51 ng/mL (range: ≤50-166 ng/mL). During the second and third weeks postpartum, 23% and 44% of the samples, respectively, had median NVP levels <50 ng/mL. Forty-five patients had plasma samples between 21 and 45 days after NVP intake assayed, and all were undetectable (Fig. 2).
The combined data set included a total of 560 concentrations from 140 women, of whom 110 were Thai, 20 were Ugandan, and 10 were American. A single-compartment model with first-order absorption was used. The model fit improved with inclusion of a lag time for absorption. Scaling the apparent volume of distribution for weight significantly improved model fit and was retained in the final model. Inclusion of covariates providing separate parameters for an elimination rate constant or apparent volume of distribution for each study population failed to improve the model. Population average pharmacokinetic parameters from the final model are presented in Table 2. A plot of the predicted NVP concentrations from our model versus the observed concentrations is presented in Figure 3. The derived elimination half-life was 55.0 hours. Simulated NVP concentration-time curves from a 1000-patient simulation using these parameters are presented in Figure 4a. Using this simulation, a graph showing the percentage of women with NVP levels greater than the assay lower limit of quantitation (50 ng/mL) and greater than the approximate IC50 for wild-type HIV (10 ng/mL) was generated for up to 28 days postpartum (see Fig. 4b).
The objective of the current study was to describe MVP elimination after intrapartum single doses to help identify the length of time postpartum during which NVP plasma concentrations remain high enough to select for resistant viruses. NVP plasma concentrations were determined in samples obtained immediately after delivery and between days 8 and 45 after delivery from Thai women who received single intrapartum NVP doses. Plasma NVP concentrations less than the assay lower limit of quantitation were observed as early as 8 days after dosing, whereas the latest sample with a detectable NVP concentration was collected on day 20 after dosing. Previous data describing the duration of NVP in plasma after a single intrapartum dose are limited. The original phase 1 studies after single doses administered during labor in Ugandan and American women stopped sampling approximately 1 week after delivery; at that time, NVP plasma concentrations were greater than 100 ng/mL in nearly all women.11,12 In a recent study of 44 HIV-negative, healthy, nonpregnant women who received a single 200-mg NVP dose, NVP remained detectable in 7 women at greater than the lower limit of assay quantitation of 150 ng/mL on the last day of sampling 22 days after dosing.18
The lower limit of quantitation of the assay used to analyze the samples from the Thai women was 50 ng/mL, greater than the ∼10 ng/mL NVP IC50 of wild-type HIV. To extrapolate to concentrations less than 50 ng/mL, we combined the Thai data with the phase 1 data from Ugandan and American women and used population analysis techniques to generate simulated NVP concentration-time curves down to 5 ng/mL. This simulation predicts that NVP concentration falls to less than 10 ng/mL in 5% of women before 11 days after dosing, in 50% of women by approximately 17.5 days after dosing, and in 95% of women by 28 days after dosing, which was consistent with the raw data from the Thai women postpartum.
NVP concentrations after intrapartum dosing demonstrate considerable variability. When the data from the Ugandan and American phase 1 studies were pooled, elimination half-life averaged 72.5 hours, with a standard deviation of 36.2 hours.19 The reason for the high interpatient variability in postpartum elimination of plasma NVP is probably multifactorial. Difference in NVP absorption rates during labor may account for some of the variability observed. Also, genetic differences could contribute to pharmacokinetic variability. NVP is metabolized by the hepatic oxidative cytochrome P450 (CYP) enzyme system, primarily the CYP3A family and, to a lesser degree, CYP2B6; however, currently defined molecular variations in the CYP3A4 gene do not seem to contribute substantially to interindividual variability in the disposition of CYP3A4 substrate drugs.20
ZDV prophylaxis was given before and during labor in addition to the single intrapartum dose, but it is known that these 2 drugs have no drug-drug interactions. The American women weighed more than the Thai and Ugandan women, but once volume of distribution was scaled for weight in the population analysis, there were no significant differences in pharmacokinetic parameters among the 3 populations.
In many developing countries, a NVP-based combination regimen is often the first-line antiretroviral regimen. These regimens are often administered as fixed-dose combination pills combining NVP with 2 nucleoside reverse transcriptase inhibitors. Many women exposed to single-dose NVP during labor are later prescribed a NVP or NNRTI-based combination when they need antiretroviral treatment for their own health. Although the clinical significance of postpartum NVP resistance on future NNRTI treatments is not fully known, data from this cohort suggest that combination regimens including NVP are less successful in terms of virologic suppression in women who recently were exposed to intrapartum single doses, indicating that NVP resistance likely contributes to these treatment failures.5 Strategies are needed to try to prevent the selection of NVP resistance after a single intrapartum dose for prevention of mother-to-child transmission of HIV (PMTCT). One proposed strategy was to use supplemental postpartum antiretroviral therapy to suppress viral replication until NVP concentrations are no longer sufficient to select for resistant HIV. Recently, preliminary data from the Treatment Options Preservation Study (TOPS) in South Africa were reported, showing a statistically significant reduction in detectable NNRTI resistance mutations in women 6 weeks after intrapartum NVP when administered 4 to 7 days of ZDV plus 3TC (50% [n = 18] versus 9% [n = 43] in women who did not receive this additional treatment).21 Also, a report on a small group of HIV-infected adults receiving chronic combination antiretroviral regimens including NVP suggests that continuation of the other antiretrovirals for 1 week after cessation of NVP may prevent the development of NVP resistance.22 Chronic nevirapine therapy results in more rapid drug elimination through autoinduction, however, resulting in a shorter duration greater than the IC50 than in pregnant women receiving only single intrapartum NVP doses. In addition, viral replication was fully suppressed in nearly all these patients before NVP was stopped, making them much less likely to select for NNRTI resistance as NVP concentrations declined. The optimal duration of supplemental postpartum antiretroviral therapy that needs to be provided is unclear. The major aim of the current analysis was to determine how long NVP persists postpartum at plasma concentrations likely to select for HIV resistance. Although the minimum concentration needed to select for the development of NVP-resistant HIV is not known, concentrations around the IC50 are likely to be sufficient. These data suggest that studies investigating the potential benefit of a short course of antiretroviral therapy after a single intrapartum NVP dose to suppress replication should continue to provide supplemental antiretrovirals for 4 weeks after delivery.
This analysis has several limitations. The simulation is not based on any direct observations of concentrations less than 50 ng/mL. NVP elimination appears linear down to the 50-ng/mL level. Our model assumes that elimination continues to be linear below this concentration and not affected by a late deep tissue distributive phase. The population pharmacokinetic model also did not include an autoinduction component, which may begin to occur even after a single dose. The population database incorporated data from 3 studies, each using different sampling designs, ethnic populations and drug assays. Nevertheless, all the assays were validated, the concentrations around delivery were equivalent among the 3 studies, and the population analysis showed no significant variation in elimination rate constant or volume of distribution among the studies, suggesting that the data from the 3 studies are suitable for combination in 1 data set for modeling.
In conclusion, these data demonstrate that plasma NVP concentrations around the IC50 may persist in some women for as long as 4 weeks after administration of single intrapartum NVP doses. With the growing use of combination antiretroviral regimens including NVP as first-line treatments for HIV-infected women around the world, prevention of postpartum NVP resistance may be important in ensuring the future well-being of mothers receiving single-dose intrapartum therapy. The preliminary data from the TOPS study suggest that 4 or 7 days of postpartum antiretroviral treatment reduces the selection of NNRTI-resistant virus. These data need to be confirmed, and based on the results of our study, the efficacy of longer postpartum treatments covering the entire NVP tail needs to be determined.
The authors thank their coinvestigators: Aram Limtrakul (Health Promotion Center Region 10, Chiang Mai), Wanmanee Matanasaravoot (Lamphun Hospital), Suraphan Sangsawang (Phayao Provincial Hospital), Jullapong Achalapong (Chiangrai Prachanukroh Hospital), Chaiwat Putiyanun (Chiang Kham Hospital), Sivaporn Jungpichanvanich (Phan Hospital), Sura Kunkongkapan (Mae Sai Hospital), Sudanee Buranabanjasatean (Mae Chan Hospital), Praparb Yuthavisuthi (Prapokklao Hospital), Jirapan Ithisuknanth (Banglamung Hospital), Nanthasak Chotivanich (Chonburi Hospital), Surabhon Ariyadej (Rayong Hospital), Somnoek Techapalokul (Klaeng Hospital), Annop Kanjanasing (Chacheongsao Hospital), Vorapin Gomuthbutra (Nakornping Hospital), Pramote Kanchanakitsakul (Somdej Prapinklao Hospital), Santhan Surawongsin (Nopparat Rajathanee Hospital), Sinart Prommas (Bhumibol Adulyadej Hospital), Woraprapa Laphikanont (Health Promotion Hospital Regional Center I), Wittaya Pornkitprasarn (Somdej Pranangchao Sirikit Hospital), Surachai Pipatnakulchai (Pranangklao Hospital), Wiroj Wannapira (Buddhachinaraj Hospital), Surachai Lamlertkittikul (Hat Yai Hospital), Chuanchom Sakondhavat (Srinagarind Hospital), Janyaporn Ratanakosol (Khon Kaen Hospital), Narong Winiyakul (Health Promotion Centre, Region 6, Khon Kaen), Nusra P. Ruttana-Aroongorn (Nong Khai Hospital), Thammanoon Sukhumanant (Samutsakorn Hospital), Yupa Srivarasat (Phaholpolphayuhasena Hospital), Bunpode Suwannachat (Kalasin Hospital), Veeradej Chalermpolprapa (Nakhonpathom Hospital), Prapan Sabsanong (Samutprakarn Hospital), Darapong Langkafa (Prajaksilapakom Army Hospital), Ruangyot Thongdej (Kranuan Crown Prince Hospital), Sakchai Tonmat (Mahasarakam Hospital), Wanchai Atthakorn (Roi-et Hospital), and Nittaya Pinyotrakool (Ratchaburi Hospital).
The authors also thank Diana Holland at the University of California, San Diego, for her advice and for providing the PACTG quality controls; Boehringer Ingelheim for providing NVP for the PHPT-2; GlaxoSmithKline for providing ZDV; the NIH AIDS Research and Reference Program, Division of AIDS, NIAID, NIH for providing NVP; and Abbott Laboratories for providing the experimental material A86093, which was used as an internal standard in the HPLC NVP assay.
1. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288:189-198.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
3. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
4. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187:725-735.
5. Cressey TR, Kunkeaw S, Ruttana-Aroongorn NP, et al. Duration of nevirapine (NVP) postpartum exposure in women who received single dose NVP during labor in addition to standard zidovudine (ZDV) prophylaxis for the prevention of mother-to-child transmission of HIV-1 in Thailand. Presented at: XV International AIDS Conference; 2004; Bangkok.
6. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
7. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951-1957.
8. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002;186:181-188.
9. Viramune (nevirapine) tablets, oral suspension, package insert labeling, revision 9. Ingelheim, Germany: Boehringer-Ingelheim Pharmaceuticals; 1998.
10. European Agency for the Evaluation of Medicinal Product. European Public Assessment Report (EPAR). February 5, 1998. Revision 3, April 16, 1999, CPMP/1096/97.
11. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998;178:368-374.
12. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479-486.
13. Aarnoutse RE, Droste JA, van Oosterhout JJ, et al. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Br J Clin Pharmacol. 2003;55:115-125.
14. Holland DT, DiFrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824-831.
15. Asqualab. International QC program for TDM in HIV infection. Nice, France: Hopital Pasteur, CHU NICE, Laboratoire de pharmacologie; 2000.
16. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guide. San Francisco: University of California, San Francisco: NONMEM Project Group; 1994.
17. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511-528.
18. Muro E, Droste J, Hofstede HT, et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose NVP: implications for intervention studies. Presented at: 11th CROI; 2004; San Francisco.
19. Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet. 2000;39:281-293.
20. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271-1294.
21. McIntyre J, Martnson N. 1413 IftT. Addition of short course Combivir (CBV) to single dose Viramune (sdNVP) for prevention of mother-to-child transmission (MTCT) of HIV-1 can significantly decrease the subsequent development of maternal NNRTI-resistant virus. Presented at: XV International AIDS Conference; 2004; Bangkok.
22. Mackie NE, Fidler S, Tamm N, et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med. 2004;5:180-184.
This article has been cited 38 time(s).
Journal of Clinical PharmacologyPopulation Pharmacokinetic Analysis of a Nevirapine-Based HIV-1 Prevention of Mother-to-Child Transmission Program in Uganda to Assess the Impact of Different Dosing Regimens for NewbornsJournal of Clinical Pharmacology
Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024
Reviews in Medical VirologyBiological mechanisms of vertical human immunodeficiency virus (HIV-1) transmissionReviews in Medical Virology
Clinical Infectious DiseasesPlasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenClinical Infectious Diseases
Bjog-An International Journal of Obstetrics and GynaecologyPreventing mother-to-child transmission of HIV: successes and challengesBjog-An International Journal of Obstetrics and Gynaecology
Clinical Infectious DiseasesEfficacy and Safety of 1-Month Postpartum Zidovudine-Didanosine to Prevent HIV-Resistance Mutations after Intrapartum Single-Dose NevirapineClinical Infectious Diseases
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment
Stopping antiretroviral therapy
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission
Plos MedicineEfficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child HIV Transmission: A Randomized Clinical TrialPlos Medicine
Journal of Antimicrobial ChemotherapyPersistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administrationJournal of Antimicrobial Chemotherapy
AIDS Research and Human RetrovirusesIntrapartum Tenofovir and Emtricitabine Reduces Low-Concentration Drug Resistance Selected by Single-Dose Nevirapine for Perinatal HIV PreventionAIDS Research and Human Retroviruses
Journal of Infectious Diseases
Single-dose nevirapine and drug resistance: The more you look, the more you find
Journal of Infectious Diseases, 192(1):
Journal of Antimicrobial ChemotherapyInfluence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai womenJournal of Antimicrobial Chemotherapy
Cochrane Database of Systematic ReviewsAntiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionCochrane Database of Systematic Reviews
Treating HIV during pregnancy - An update on safety issues
Drug Safety, 29(6):
American Journal of Obstetrics and GynecologyUse of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?American Journal of Obstetrics and Gynecology
American Journal of Obstetrics and GynecologyInternational recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 updateAmerican Journal of Obstetrics and Gynecology
Journal of Infectious DiseasesAssociations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African AmericansJournal of Infectious Diseases
PharmacogenomicsPharmacogenomics and the prevention of mother-to-child transmission of HIVPharmacogenomics
Antimicrobial Agents and ChemotherapyImpact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childrenAntimicrobial Agents and Chemotherapy
Clinical Infectious DiseasesPrevention in Neglected Subpopulations: Prevention of Mother-to-Child Transmission of HIV InfectionClinical Infectious Diseases
Expert Opinion on PharmacotherapyControversies in the use of nevirapine for prevention of mother-to-child transmission HIVExpert Opinion on Pharmacotherapy
Theoretical Biology and Medical ModellingTransient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutationsTheoretical Biology and Medical Modelling
Antimicrobial Agents and ChemotherapyLack of Pharmacokinetic Interaction between Amdoxovir and Reduced- and Standard-Dose Zidovudine in HIV-1-Infected IndividualsAntimicrobial Agents and Chemotherapy
Clinical Drug Investigation
Antiretroviral therapy for prevention of mother-to-child HIV transmission - Focus on single-dose nevirapine
Clinical Drug Investigation, 26():
Clinical Infectious DiseasesPersistence of nevirapine in breast milk after discontinuation of treatmentClinical Infectious Diseases
HIV-1 transmission cluster with M41L 'singleton' mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men
Antiviral Therapy, 11(8):
Antimicrobial Agents and ChemotherapyPharmacokinetics of Phase I Nevirapine Metabolites following a Single Dose and at Steady StateAntimicrobial Agents and Chemotherapy
Current Opinion in Infectious DiseasesStrategies to prevent mother-to-child transmission of HIVCurrent Opinion in Infectious Diseases
Current Opinion in Infectious DiseasesPostexposure prophylaxis after sexual exposure to HIVCurrent Opinion in Infectious Diseases
JAIDS Journal of Acquired Immune Deficiency SyndromesQuantitative Analysis of HIV-1 Variants With the K103N Resistance Mutation After Single-Dose Nevirapine in Women With HIV-1 Subtypes A, C, and DJAIDS Journal of Acquired Immune Deficiency Syndromes
JAIDS Journal of Acquired Immune Deficiency SyndromesIndependent Effects of Nevirapine Prophylaxis and HIV-1 RNA Suppression in Breast Milk on Early Perinatal HIV-1 TransmissionJAIDS Journal of Acquired Immune Deficiency Syndromes
nevirapine; prevention mother-to-child HIV transmission; pharmacokinetics
© 2005 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.